11,981 Shares in SI-BONE, Inc. (NASDAQ:SIBN) Bought by Semanteon Capital Management LP

Semanteon Capital Management LP purchased a new position in SI-BONE, Inc. (NASDAQ:SIBN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 11,981 shares of the company’s stock, valued at approximately $251,000.

A number of other hedge funds also recently modified their holdings of SIBN. Assenagon Asset Management S.A. increased its position in shares of SI-BONE by 92.3% in the fourth quarter. Assenagon Asset Management S.A. now owns 419,940 shares of the company’s stock worth $8,815,000 after purchasing an additional 201,615 shares during the period. Vanguard Group Inc. grew its position in SI-BONE by 7.2% in the third quarter. Vanguard Group Inc. now owns 2,308,516 shares of the company’s stock valued at $49,033,000 after acquiring an additional 155,121 shares during the last quarter. Impax Asset Management Group plc grew its position in SI-BONE by 35.7% in the third quarter. Impax Asset Management Group plc now owns 475,343 shares of the company’s stock valued at $10,096,000 after acquiring an additional 125,000 shares during the last quarter. New York State Common Retirement Fund grew its position in SI-BONE by 17.7% in the third quarter. New York State Common Retirement Fund now owns 376,943 shares of the company’s stock valued at $8,006,000 after acquiring an additional 56,630 shares during the last quarter. Finally, Federated Hermes Inc. grew its position in SI-BONE by 20.5% in the third quarter. Federated Hermes Inc. now owns 325,721 shares of the company’s stock valued at $6,918,000 after acquiring an additional 55,515 shares during the last quarter. Institutional investors own 98.11% of the company’s stock.

Insider Buying and Selling

In related news, insider Anthony J. Recupero sold 3,330 shares of SI-BONE stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $16.82, for a total value of $56,010.60. Following the transaction, the insider now directly owns 255,760 shares of the company’s stock, valued at $4,301,883.20. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, insider Anthony J. Recupero sold 3,330 shares of SI-BONE stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $16.82, for a total value of $56,010.60. Following the transaction, the insider now directly owns 255,760 shares of the company’s stock, valued at $4,301,883.20. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Anshul Maheshwari sold 2,425 shares of SI-BONE stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $15.45, for a total value of $37,466.25. Following the completion of the transaction, the chief financial officer now directly owns 205,516 shares in the company, valued at $3,175,222.20. The disclosure for this sale can be found here. Insiders have sold a total of 11,562 shares of company stock valued at $185,285 over the last ninety days. 5.40% of the stock is owned by company insiders.

SI-BONE Price Performance

Shares of SIBN stock opened at $14.57 on Friday. The business’s 50-day moving average price is $16.72 and its 200-day moving average price is $18.19. SI-BONE, Inc. has a 12 month low of $14.12 and a 12 month high of $29.51. The company has a debt-to-equity ratio of 0.21, a current ratio of 9.01 and a quick ratio of 8.15.

SI-BONE (NASDAQ:SIBN) last posted its quarterly earnings data on Monday, February 26th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.02. The company had revenue of $38.86 million for the quarter, compared to analyst estimates of $38.60 million. SI-BONE had a negative return on equity of 28.22% and a negative net margin of 31.20%. As a group, equities analysts expect that SI-BONE, Inc. will post -0.98 earnings per share for the current year.

Analysts Set New Price Targets

SIBN has been the topic of a number of recent analyst reports. Truist Financial reiterated a “buy” rating and issued a $24.00 target price (down previously from $26.00) on shares of SI-BONE in a research report on Tuesday, February 27th. Piper Sandler initiated coverage on SI-BONE in a research report on Thursday, March 28th. They issued an “overweight” rating and a $25.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $27.00 target price on shares of SI-BONE in a research report on Wednesday, April 3rd. Morgan Stanley lifted their price target on SI-BONE from $25.00 to $26.00 and gave the company an “overweight” rating in a research note on Tuesday, February 27th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price target on shares of SI-BONE in a research note on Tuesday, February 27th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $26.67.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.